Introduction {#sec1}
============

Allogeneic stem cell transplantation (SCT) represents an increasingly important curative option in adults with high-risk acute myeloid leukemia (AML) [@bib1]. To a large degree, this reflects the improved tolerability of reduced-intensity conditioning (RIC) regimens, which have permitted the extension of a potentially curative graft-versus-leukemia (GVL) effect to patients up to their eighth decade [@bib2], [@bib3], [@bib4]. Although the increased availability of allogeneic transplantation represents a major advance in the treatment of older adults with AML, its curative potential remains limited by both disease relapse and graft-versus-host disease (GVHD), which now represent the 2 major causes of treatment failure [@bib5]. Thirty percent to 80% of patients allografted for AML will relapse; the great majority in the first 12 months after transplantation, and the outcome for this patient population remains extremely poor [@bib6].

The administration of cellular or pharmacological therapies with the ability to either augment a GVL effect or deliver direct antitumor activity after transplantation represents a promising strategy to reduce the risk of disease relapse. However, because the preponderance of patients allografted for AML relapse within the first year after transplantation, any intervention aimed at reducing the risk of relapse must be delivered early. Although donor lymphocyte infusions (DLI) have the potential to augment a GVL effect, they are associated with a significant risk of severe GVHD, particularly when administered early after transplantation, which complicates their routine utilization [@bib7], [@bib8]. In contrast, pharmacological agents can, in principle, be administered early after transplantation, and consequently are the subject of increasing scrutiny as a strategy to reduce the risk of disease relapse after transplantation [@bib9], [@bib10], [@bib11].

Azacitidine (AZA) is a DNA methyltransferase inhibitor that demonstrates significant clinical activity in AML and myelodysplasia [@bib12], [@bib13] and can also be an effective salvage therapy in patients who relapse after allogeneic transplantation [@bib14], [@bib15]. It has been postulated that the antileukemic activity of AZA after transplantation may, in part at least, be a consequence of the upregulation of epigenetically silenced minor histocompatibility and tumor antigens on leukemic blasts, resulting in an augmented GVL response [@bib16], [@bib17], [@bib18]. This is supported by the observation that AZA has the capacity to induce a CD8^+^ T cell response to a range of tumor antigens in patients with AML both before and after transplantation [@bib16], [@bib17]. Separately, AZA has been shown to augment the reconstitution of T regulatory cells (Tregs) in the immediate post-transplantation period and, in mouse models, its administration reduces the risk of severe GVHD [@bib17], [@bib19], [@bib20], [@bib21]. Taken together, these data raise the possibility that post-transplantation AZA may either deliver a direct antitumor effect or epigenetically manipulate the allo-immune response, augmenting a GVL effect without increasing the risk of GVHD [@bib22]. To date, however, there has been no systematic study of the clinical activity of adjunctive post-transplantation AZA when administered as a maintenance strategy. Two small studies have identified the maximum tolerated dose of AZA after transplantation. None to date have studied the impact of sustained administration of hypomethylating agents on clinical outcome [@bib10], [@bib11]. We, therefore, now report clinical outcomes in a cohort of patients with AML who underwent transplantation using a standardized RIC regimen incorporating post-transplantation AZA in the RICAZA study.

Patients and Methods {#sec2}
====================

Patient Inclusion {#sec2.1}
-----------------

Adult patients with AML whose outcome with conventional chemotherapy was predicted to be poor, in whom a matched related donor or matched unrelated donor had been identified, were eligible for this trial. The clinical trial protocol was approved by the research ethics committee and all patients gave informed consent in accordance with the Declaration of Helsinki. The trial was registered at <http://isrctn.org> as \#ISRCTN36825171. The primary endpoint of the study was to assess the safety and tolerability of AZA in patients after RIC allogeneic transplantation for AML. The impact of AZA administration on biological parameters in the first 27 patients treated on the RICAZA study have been reported in a previous publication, but with a median follow-up of 7 months, it was not possible to comment on the impact of AZA administration on clinical outcomes [@bib17]. In this paper, we report an updated analysis of the 37 patients treated on the RICAZA study with a median follow-up of 24 months (range, 6 to 28 months).

Transplantation Regimen {#sec2.2}
-----------------------

Patients who underwent allogeneic SCT using either a conditioning regimen consisting of fludarabine (30 mg/m^2^ intravenously for 5 days), melphalan (140 mg/m^2^ intravenously), and alemtuzumab (10 mg intravenously for 5 days) (n = 34) or a FLAMSA regimen (n = 3) were eligible for this trial [@bib23]. GVHD prophylaxis consisted of cyclosporine commencing day −1 at an adjusted dose to achieve therapeutic levels between 100 μg/L and 200 μg/L after transplantation, with the aim of tapering immunosuppression in patients with no evidence of active GVHD between day 60 and day 90 after transplantation. Patients were not eligible to receive DLI in the first year after transplantation.

AZA Schedule {#sec2.3}
------------

Patients with stable engraftment (neutrophil count: \>1 × 10^9^/L; platelet count: \>50 × 10^9^/L) commenced treatment with AZA on day +42 after transplantation at a dose of 36 mg/m^2^ subcutaneously for 5 days. This was administered every 28 days up to 12 months after transplantation. Toxicity was graded against the National Cancer Institute\'s Common Terminology Criteria for Adverse Events. The dose of AZA was reduced to 24 mg/m^2^ in patients experiencing grade 3 or 4 hematologic toxicity that persisted for \>2 weeks. Initial data concerning the tolerability of post-transplantation AZA in a cohort of 27 patients, of whom only 17 had received more than 6 courses of post-transplantation AZA, were presented in a previous publication [@bib17] and we now report the final toxicity and clinical outcome data in the complete trial cohort of 37 patients. The presence of active acute GVHD or a history of GVHD were not exclusion criteria to trial entry. Clinical responses and transplantation outcome were assessed every 3 months by sequential bone marrow aspirates and peripheral blood lineage specific chimerism analyses, as previously described, until 12 months after transplantation.

Quantification of Circulating Tumor-specific CD8^+^ T Cells {#sec2.4}
-----------------------------------------------------------

The number of circulating tumor-specific cytotoxic T lymphocytes was measured in peripheral blood mononuclear cells prepared from 50 mL of fresh peripheral blood using a CD137 expression and enrichment assay (Miltenyi Biotec, Bergisch Gladbach, Germany). The procedure was conducted as previously described with some minor adjustments [@bib17], [@bib24], [@bib25]. The HLA type of each patient was known and peptides that matched the HLA type were chosen from the list of previously described tumor-associated antigens [@bib17]. The frequency of CD137^+^ antigen-specific T cells was calculated as a percentage of the total CD8^+^ T cell pool from the pre-enrichment estimates. The postenrichment analysis was used to validate the results obtained in pre-enrichment samples.

Statistical Analysis {#sec2.5}
--------------------

Safety and tolerability outcomes were defined in terms of hematological and nonhematological toxicities. Studied outcomes included rates of complete remission (CR), relapse-free survival (RFS), and overall survival (OS). *RFS* was defined as the time from transplantation to relapse or death, censoring alive patients at date last seen. *OS* was defined as time from transplantation to death, censoring alive patients at date last seen. The sample size was calculated using A\'Herns single stage design and was based on the primary outcome measure of tolerability. A tolerability rate of 50% or less was deemed to be unacceptable and the probability of obtaining a false positive result was set at 5%. A tolerability rate of 70% was deemed to be an acceptable figure and the probability of a false negative result (ie, incorrectly rejecting for further study a treatment with a true tolerability rate of \>70%) was set at 10%. The analysis reported is based on the per-protocol population, including all patients who received the protocol-defined RIC regimen and commenced AZA after transplantation. Statistical analyses were performed using STATA 12 and R version 3.1.

Results {#sec3}
=======

Patient Demographics {#sec3.1}
--------------------

Fifty-one patients were registered for treatment on the RICAZA trial and underwent allogeneic transplantation. Fourteen patients did not commence AZA therapy because of post-transplantation complications, including infection (n = 8), patient withdrawal of consent or ineligibility (n = 5), or acute GVHD (n = 1). Thirty-seven patients commenced monthly courses of AZA at a median time of 54 days after transplantation (range, 40 to 194 days) and are the subject of this report. The median follow-up for alive patients was 24 months (range, 6 to 28 months). The median age of the 37 patients who commenced AZA was 60 years (range, 40 to 71 years) ([Table 1](#tbl1){ref-type="table"}). Twenty-four patients (65%) were in CR1, 8 patients (22%) were in CR2, 3 patients (8%) were in first relapse, and 2 patients (5%) had primary refractory disease ([Table 1](#tbl1){ref-type="table"}). Thirteen (35%) patients underwent transplantation using a matched related donor and 24 (65%) had an adult volunteer unrelated donor. Thirty-four patients received granulocyte colony--stimulating factor--mobilized peripheral blood stem cells and 3 had bone marrow as the stem cell source. All patients engrafted with a median time to neutrophil engraftment of 13 days (range, 1 to 22 days) and a median time to platelet engraftment of 13 days (range, 10 to 33 days).

Tolerability of Post-transplantation AZA {#sec3.2}
----------------------------------------

AZA was well tolerated in the majority of patients. Hematological and nonhematological toxicities experienced by 10% or more of patients are described in [Table 2](#tbl2){ref-type="table"}. Four patients experienced treatment delays due to neutropenia or thrombocytopenia. The most common nonhematological toxicities observed were abnormalities of liver function, injection site reaction, nausea, and infection. Thirty-one patients completed at least 3 cycles of AZA and 16 patients completed 10 cycles. Twenty patients discontinued AZA before 12 months after transplantation because of disease relapse (n = 10), infection or hematological toxicity (n = 6), or miscellaneous reasons (eg, physician decision to administer DLI, withdrawal of consent, and protocol deviation) (n = 4).

Chimerism, GVHD, Relapse, and Outcome {#sec3.3}
-------------------------------------

At day +90 after transplantation, 22 (59%) patients demonstrated full donor chimerism in whole blood, of whom 7 (19%) demonstrated full donor chimerism in the T cell fraction. Serial chimerism studies are available on 14 patients who received AZA after transplantation, which demonstrate broad stability of T cell chimerism with no significant changes observed over time. Grade 1 or 2 acute GVHD was documented in 17 patients. No patient developed severe (grades 3 or 4) acute GVHD during the period of treatment on the RICAZA trial, although 1 patient developed severe GVHD after being withdrawn and receiving DLI for the treatment of disease relapse. Ten patients developed limited chronic GVHD but no patient developed extensive chronic GVHD.

The day 100 nonrelapse mortality was 0% and the 1-year nonrelapse mortality was 8% (all infectious deaths). A total of 19 (51%) patients died (disease relapse, n = 16; infection, n = 2; DLI-induced GVHD, n = 1). The median time to disease relapse was 8 months after transplantation (range, 5 to 11 months). The 1-year and 2-year OS were 81% (95% confidence interval \[CI\], 69% to 95%) and 49% (95% CI, 35% to 68%), respectively. The 1-year and 2-year RFS were 57% (95% CI, 43% to 75%) and 49% (95% CI, 35% to 68%), respectively.

Correlation of Peripheral Blood Antitumor CD8-specific T Cell Response with Clinical Outcome {#sec3.4}
--------------------------------------------------------------------------------------------

Twenty-eight patients treated with AZA were screened for antitumor CD8^+^ T cell responses to a range of tumor antigens. AZA induced a CD8^+^ T cell response to 1 or more tumor-specific peptides in 16 patients. A summary of their characteristics by CD8 T cell response is displayed in [Table 3](#tbl3){ref-type="table"}. As previously reported, no CD8^+^ T cell response was detected in 7 patients allografted using a similar conditioning regimen who did not receive AZA after transplantation [@bib17]. The frequency of CD8^+^ T cells directed against the studied tumor antigens ranged from .01% to 1.6% (mean, .45%) of circulating CD8^+^ T cells, which is comparable to the frequency of cytomegalovirus-specific T cell responses detectable in cytomegalovirus-seropositive patients. Induction of a CD8^+^ anti-tumor response was associated with a reduction in relapse risk taking into account death as a competing risk (hazard ratio \[HR\], .30; 95% CI, .10 to .85; *P* = .02) and improved RFS (HR, .29; 95% CI, .10 to .83; *P* = .02) ([Figure 1](#fig1){ref-type="fig"}). The beneficial impact of detection of a CD8^+^ T cell response to candidate tumor antigens on relapse risk and RFS is still observed, with adjustment for time to start of AZA therapy (HR, .30; 95% CI, .1 to .94; *P* = .039) or if restricted to only 24 patients who commenced AZA before day +90 after transplantation (HR, .32; 95% CI, .10 to .95; *P* = .041) in the competing risk analysis.

The impact of detection of a CD8^+^ T cell response on relapse risk remains strong with adjustment of donor type (HR, .26; 95% CI, .09 to .70; *P* = .008) and with additional adjustment of start time to AZA therapy after transplantation (HR, .27; 95% CI, .09 to .82; *P* = .022). There was no correlation between the timing or magnitude of the CD8^+^ tumor response and relapse risk.

Discussion {#sec4}
==========

The ability of epigenetic therapies to upregulate tumor antigens represents a novel strategy by which a GVL response may be augmented. In this small prospective trial, we observed a reduced risk of disease relapse in patients treated with post-transplantation AZA who developed a CD8^+^ T cell response to a range of candidate tumor antigens. It is important to emphasize the importance of repeating this observation in a larger randomized study, but these data are supportive of further investigation of the impact of other post-transplantation epigenetic therapies, such as DNA methyltransferase inhibitor and histone deacetylase inhibitors, on transplantation outcome. Of interest, the dose of AZA observed to induce a CD8^+^ T cell response in this study is approximately one-half that utilized in the treatment of patients with *de novo* AML or myelodysplasia, consistent with the hypothesis that the observed reduction in relapse is consequent upon manipulation of the alloreactive response. Our study appears to refute the possibility that AZA might improve/outcome by simply postponing relapse, although a larger study will clearly be required to conclusively address this possibility. Because the great majority of patients destined to relapse after an allogeneic transplantation for AML will do so within the first year, a potential advantage of AZA administration, as opposed to DLI, is the ability to commence treatment early [@bib6]. The majority of patients in this study were not only able to commence AZA within 3 months after transplantation but also complete the scheduled course of 1-year treatment. Nonetheless, approximately one third of the patients registered to this study did not receive AZA, emphasizing the potential limitations of post-transplantation interventions as a strategy to reduce the risk of disease relapse. Alternative approaches to selectively augment a GVL effect include vaccination to tumor antigens, such as WT1, and it would be of interest to combine such a strategy with AZA, as has been done for DLI [@bib26], [@bib27]. Furthermore, although in this study we measured T cell responses to a broad range of candidate tumor antigens, future studies should be aimed at correlating clinical outcome with the induction of immune responses to specific tumor antigens.

A number of studies have demonstrated the ability of AZA to accelerate the reconstitution of Tregs after allogeneic SCT [@bib17], [@bib21], and in murine models this has been correlated with a reduction in the incidence of GVHD [@bib19]. Although the observation that no patient who received post-transplantation AZA had extensive chronic GVHD is striking, particularly given the fact that most patients underwent transplantation using an unrelated donor, it is important to note that the RIC regimen utilized included alemtuzumab, which is known to reduce the incidence of both acute and chronic GVHD [@bib28], [@bib29]. Nonetheless, these data support further examination of the impact of post-transplantation AZA on the incidence of acute or chronic GVHD. Reassuringly, our data suggest that the observed induction of Tregs and attendant absence of extensive chronic GVHD do not appear to be associated with an increased risk of disease relapse [@bib22].

This is the first study to examine the impact of the post-transplantation administration of AZA on transplantation outcome. The reduced relapse rate in patients who demonstrate a CD8^+^ T cell response directed against tumor antigens, coupled with the absence of chronic extensive GVHD, is consistent with the hypothesis that AZA has the capacity to epigenetically manipulate the alloreactive effect after transplantation. These observations require confirmation in a prospective randomized trial.
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###### 

Demographics of Study Population

  Characteristic                              Value
  ------------------------------------------- ------------
  Diagnosis                                   
   AML, de novo                               24
   AML, secondary                             13
  Karyotype                                   
   Intermediate                               30
   Poor                                       7
  Age, median (range), yr                     60 (40-71)
  Sex                                         
   Male                                       21
   Female                                     16
  Disease status at time of transplantation   
   CR1                                        24
   CR2                                        8
   First relapse                              3
   Primary refractory disease                 2
  Conditioning treatment                      
   Fludarabine, melphalan, alemtuzumab        34
   Fludarabine, cytarabine, amsacrine         3
  Donor type                                  
   Sibling                                    13
   Matched unrelated donor                    24
  CMV status (patient/donor)                  
   Positive/positive                          14
   Positive/negative                          6
   Negative/positive                          3
   Negative/negative                          14
  Stem cell source                            
   Peripheral blood                           34
   Bone marrow                                3

CMV indicates cytomegalovirus.

###### 

Summary of Hematological and Nonhematological Adverse Events Occurring in \>10% of the Patient Population

                                                                                                                            Grades 1-2   Grades 3-4   Total
  ------------------------------------------------------------------------------------------------------------------------- ------------ ------------ -------
  Hematological Adverse Event                                                                                                                         
   Anemia                                                                                                                   16           10           26
   Thrombocytopenia                                                                                                         10           13           23
   Neutropenia                                                                                                              3            10           13
  Nonhematological Adverse Event                                                                                                                      
   Laboratory investigations -- biochemistry                                                                                75           10           85
   Gastrointestinal (inc. nausea, vomiting, diarrhea, constipation, anorexia)                                               71           2            73
   Infection                                                                                                                35           19           54
   Injection site reaction                                                                                                  28           0            28
   Pain                                                                                                                     21           2            23
   Dermatology/skin (rash, mucositis, pruritus, shingles, dry skin, bruising, itching, peeling epidermis, skin breakdown)   21           0            21
   Fatigue/lethargy                                                                                                         20           0            20
   Pulmonary/upper respiratory (cough, dyspnea, hypoxia)                                                                    12           1            13
   Neurology (headache, depression, apnea, syncope)                                                                         7            2            9
   Fever                                                                                                                    6            1            8
   Cold/flu-like symptoms                                                                                                   8            0            8
   Edema                                                                                                                    4            0            4

###### 

Demographics of Patients with CD8 T Cell Response

  Characteristic                                                 CD8 Negative (n = 12)   CD8 Positive (n = 16)
  -------------------------------------------------------------- ----------------------- -----------------------
  Age, years (mean, range)                                       61 (41-70)              59 (49-71)
  Sex                                                                                    
   Male                                                          7                       10
   Female                                                        5                       6
  Disease status at time of transplantation                                              
   CR1                                                           8                       11
   CR2                                                           3                       4
   First relapse                                                 1                       1
  Donor type                                                                             
   Sibling                                                       4                       8
   Matched unrelated donor                                       8                       8
  CMV status (patient/donor)                                                             
   Positive/positive                                             4                       7
   Positive/negative                                             3                       2
   Negative/positive                                             0                       3
   Negative/negative                                             5                       4
  Stem cell source                                                                       
   Peripheral blood                                              11                      15
   Bone marrow                                                   1                       1
  Time from transplantation to start of AZA, median (range), d   47 (40-81)              57 (40-194)
